Sophiris Bio, a urology company, has announced that PRX302, a treatment for benign prostatic hyperplasia (BPH), was well-tolerated for three months following a transrectal injection.

The transrectal safety study was designed to assess the safety and tolerability of delivering PRX302 via a transrectal route of administration using transrectal ultrasound (TRUS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results support the use of a TRUS-guided injection for the delivery of PRX302 directly into the prostate; previous studies used a transperineal route.

Sophiris Bio CEO Randall Woods said that the decision to move to a transrectal route was made based on the input of advisors and leading urologists treating patients with BPH.

“The transrectal route enables PRX302 to be administered by a urologist in an office based setting, in a brief procedure that does not require catheterisation,” Woods said.

“To date 126 patients with BPH have been treated with PRX302 with a similar safety and tolerability profile between the transrectal and transperineal routes of administration.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ongoing placebo controlled, double-blind, Phase I-II study, which randomised 40 patients within one of four ascending dose cohorts, has found PRX302 continues to be well-tolerated with an adverse event profile similar to previous clinical studies using a transperineal injection.

The multicentre study also observed the improvement in the International Prostate Symptom Score (IPSS) in all cohorts.

PRX302 is designed to be a single treatment for the long-term relief of BPH symptoms, such as restricted urinary flow from enlarged prostate, without causing sexual dysfunction or sacrificing quality of life, according to the company.